Dysfunction of the mTOR pathway is a risk factor for Alzheimer's disease

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Yates, Sharon C ^a   Zafar, Amen ^a   Hubbard, Paul ^a   Nagy, Sheila ^a   Durant, Sarah ^a   Bicknell, Roy ^a   Wilcock, Gordon ^b   Christie, Sharon ^b   Esiri, Margaret M ^b   Smith, A David ^c   Nagy, Zsuzsanna ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Alzheimer's disease; ApoE; Cell cycle; MTOR; Risk factor

Indexed keywords

EID: 85005916271     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/2051-5960-1-3     Document Type: Article

References (47)

1. Fjell AM, Walhovd KB: Neuroimaging results impose new views on Alzheimer's disease-the role of amyloid revised. Mol Neurobiol 2012, 45: 153-72. 10.1007/s12035-011-8228-7
2. Reitz C: Alzheimer's disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis 2012, 2012: 369808.
3. Arendt T, Bruckner MK: Linking cell-cycle dysfunction in Alzheimer's disease to a failure of synaptic plasticity. Biochim Biophys Acta 2007, 1772: 413-21. 10.1016/j.bbadis.2006.12.005
4. Nagy Z, Esiri MM, Smith AD: The cell division cycle and the pathophysiology of Alzheimer's disease. Neuroscience 1998, 87: 731-9.
5. Arendt T: Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization. Neuroscience 2001, 102: 723-65. 10.1016/S0306-4522(00)00516-9
6. Arendt T: Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the 'Dr. Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and yang of neuroplasticity. Prog Neurobiol 2003, 71: 83-248. 10.1016/j.pneurobio.2003.09.007
7. Nagy Z: The last neuronal division: a unifying hypothesis for the pathogenesis of Alzheimer's disease. J Cell Mol Med 2005, 9: 531-41. 10.1111/j.1582-4934.2005.tb00485.x
8. Gibbons JJ, Abraham RT, Yu K: Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol 2009,36(Suppl 3):S3-S17.
9. Ma XM, Blenis J: Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009, 10: 18-307.
10. Hoeffer CA, Klann E: mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci 2010, 33: 67-75. 10.1016/j.tins.2009.11.003
11. Jaworski J, Spangler S, Seeburg DP, Hoogenraad CC, Sheng M: Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway. J Neurosci 2005, 25: 11300-12. 10.1523/JNEUROSCI.2270-05.2005
12. Ma T, Hoeffer CA, Capetillo-Zarate E, Yu F, Wong H, Lin MT, Tampellini D, Klann E, Blitzer RD, Gouras GK: Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. PLoS One 2010., 5:
13. Zeng LH, McDaniel S, Rensing NR, Wong M: Regulation of cell death and epileptogenesis by the mammalian target of rapamycin (mTOR): a double-edged sword? Cell Cycle 2010, 9: 2281-5. 10.4161/cc.9.12.11866
14. Zeng LH, Rensing NR, Wong M: Developing Antiepileptogenic Drugs for Acquired Epilepsy: Targeting the Mammalian Target of Rapamycin (mTOR) Pathway. Mol Cell Pharmacol 2009, 1: 124-9. 10.4255/mcpharmacol.09.16
15. Zeng LH, Rensing NR, Wong M: The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci 2009, 29: 6964-72. 10.1523/JNEUROSCI.0066-09.2009
16. Chen S, Atkins CM, Liu CL, Alonso OF, Dietrich WD, Hu BR: Alterations in mammalian target of rapamycin signaling pathways after traumatic brain injury. J Cereb Blood Flow Metab 2007, 27: 939-49.
17. Erlich S, Alexandrovich A, Shohami E, Pinkas-Kramarski R: Rapamycin is a neuroprotective treatment for traumatic brain injury. Neurobiol Dis 2007, 26: 86-93. 10.1016/j.nbd.2006.12.003
18. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S: Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem 2010, 285: 13107-20. 10.1074/jbc.M110.100420
19. Swiech L, Perycz M, Malik A, Jaworski J: Role of mTOR in physiology and pathology of the nervous system. Biochim Biophys Acta 2008, 1784: 116-32. 10.1016/j.bbapap.2007.08.015
20. Nagy Z, Combrinck M, Budge M, McShane R: Cell cycle kinesis in lymphocytes in the diagnosis of Alzheimer's disease. Neurosci Lett 2002, 317: 81-4. 10.1016/S0304-3940(01)02442-9
21. Paccalin M, Pain-Barc S, Pluchon C, Paul C, Besson MN, Carret-Rebillat AS, Rioux-Bilan A, Gil R, Hugon J: Activated mTOR and PKR kinases in lymphocytes correlate with memory and cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2006, 22: 6-320.
22. Zhou X, Jia J: P53-mediated G(1)/S checkpoint dysfunction in lymphocytes from Alzheimer's disease patients. Neurosci Lett 2010, 468: 320-5. 10.1016/j.neulet.2009.11.024
23. An WL, Cowburn RF, Li L, Braak H, Alafuzoff I, Iqbal K, Iqbal IG, Winblad B, Pei JJ: Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am J Pathol 2003, 163: 591-607. 10.1016/S0002-9440(10)63687-5
24. Li X, Alafuzoff I, Soininen H, Winblad B, Pei JJ: Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J 2005, 272: 4211-20. 10.1111/j.1742-4658.2005.04833.x
25. Li X, An WL, Alafuzoff I, Soininen H, Winblad B, Pei JJ: Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain. Neuroreport 2004, 15: 2237-40. 10.1097/00001756-200410050-00019
26. Pei JJ, An WL, Zhou XW, Nishimura T, Norberg J, Benedikz E, Gotz J, Winblad B: P70 S6 kinase mediates tau phosphorylation and synthesis. FEBS Lett 2006, 580: 107-14. 10.1016/j.febslet.2005.11.059
27. Pei JJ, Hugon J: mTOR-dependent signalling in Alzheimer's disease. J Cell Mol Med 2008, 12: 2525-32. 10.1111/j.1582-4934.2008.00509.x
28. Lafay-Chebassier C, Perault-Pochat MC, Page G, Rioux BA, Damjanac M, Pain S, Houeto JL, Gil R, Hugon J: The immunosuppressant rapamycin exacerbates neurotoxicity of Abeta peptide. J Neurosci Res 2006, 84: 1323-34. 10.1002/jnr.21039
29. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, Richardson A, Strong R, Galvan V: Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One 2010, 5: e9979. 10.1371/journal.pone.0009979
30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34: 939-44. 10.1212/WNL.34.7.939
31. Petersen RC, Knopman DS: MCI is a clinically useful concept. Int Psychogeriatr 2006, 18: 394-402.
32. Braak H, Braak E: Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995, 16: 271-8. 10.1016/0197-4580(95)00021-6
33. Moravec R: Total Cell Quantitation Using the CytoTox 96(TM) Non-Radioactive Cytotoxicity Assay. 45 Edition45; 1994:7-10.
34. Ormerod M, In: Ormerod M, editor (ed): Analysis of DNA - general methods. Oxford University Press, Oxford: Flow Cytometry: A Practical Approach, 3 edn; 2000:83-97.
35. Linton K, Howarth C, Wappett M, Newton G, Lachel C, Iqbal J, Pepper S, Byers R, Chan WJ, Radford J: Microarray gene expression analysis of fixed archival tissue permits molecular classification and identification of potential therapeutic targets in diffuse large B-cell lymphoma. J Mol Diagn 2012, 14: 223-32. 10.1016/j.jmoldx.2012.01.008
36. Lucas A, Lin G: Gene Expression Microarray Analysis of Archival FFPE Samples. Agilent: Application Note, Gene Expression Analysis; 2009.
37. Opitz L, Salinas-Riester G, Grade M, Jung K, Jo P, Emons G, Ghadimi BM, Beissbarth T, Gaedcke J: Impact of RNA degradation on gene expression profiling. BMC Med Genomics 2010, 3: 36. 10.1186/1755-8794-3-36
38. Weis S, Llenos IC, Dulay JR, Elashoff M, Martinez-Murillo F, Miller CL: Quality control for microarray analysis of human brain samples: The impact of postmortem factors, RNA characteristics, and histopathology. J Neurosci Methods 2007, 165: 198-209. 10.1016/j.jneumeth.2007.06.001
39. Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998, 95: 14863-8. 10.1073/pnas.95.25.14863
40. Xu PT, Li YJ, Qin XJ, Scherzer CR, Xu H, Schmechel DE, Hulette CM, Ervin J, Gullans SR, Haines J, Pericak-Vance MA, Gilbert JR: Differences in apolipoprotein E3/3 and E4/4 allele-specific gene expression in hippocampus in Alzheimer disease. Neurobiol Dis 2006, 21: 256-75. 10.1016/j.nbd.2005.07.004
41. Gonzalez J, Harris T, Childs G, Prystowsky MB: Rapamycin blocks IL-2-driven T cell cycle progression while preserving T cell survival. Blood Cells Mol Dis 2001, 27: 572-85. 10.1006/bcmd.2001.0420
42. Xu PT, Li YJ, Qin XJ, Kroner C, Green-Odlum A, Xu H, Wang TY, Schmechel DE, Hulette CM, Ervin J, Hauser M, Haines J, Pericak-Vance MA, Gilbert JR: A SAGE study of apolipoprotein E3/3, E3/4 and E4/4 allele-specific gene expression in hippocampus in Alzheimer disease. Mol Cell Neurosci 2007, 36: 313-31. 10.1016/j.mcn.2007.06.009
43. Avramopoulos D, Szymanski M, Wang R, Bassett S: Gene expression reveals overlap between normal aging and Alzheimer's disease genes. Neurobiol Aging; 2010.
44. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW: Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A 2004, 101: 2173-8. 10.1073/pnas.0308512100
45. Tan MG, Chua WT, Esiri MM, Smith AD, Vinters HV, Lai MK: Genome wide profiling of altered gene expression in the neocortex of Alzheimer's disease. J Neurosci Res 2010, 88: 1157-69.
46. Bossers K, Wirz KT, Meerhoff GF, Essing AH, van Dongen JW, Houba P, Kruse CG, Verhaagen J, Swaab DF: Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease. Brain 2010, 133: 3699-723. 10.1093/brain/awq258
47. Tanzi RE: The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2012., 2: